International Primary Ciliary Dyskinesia Cohort

Primary Ciliary Dyskinesia Clinical Trial

— iPCD  

Official title:

International Primary Ciliary Dyskinesia Cohort

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03517865
• Other study ID #: iPCD cohort
• Status: Recruiting
• Start date: January 2013
• Est. completion date: December 2030

Study information

• Verified date: November 2023
• Source: University of Bern
• Contact: Claudia E Kuehni, Prof
• Phone: 0041 316313507
• Email: claudia.kuehni[@]unibe.ch
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The iPCD Cohort is an international cohort that assembles available retrospective datasets and prospectively newly collected clinical and diagnostic data from patients suffering from primary ciliary dyskinesia (PCD) worldwide, to answer pertinent questions on clinical phenotype, disease severity, prognosis and effect of treatments in patients with this rare multiorgan disease.

Description:

The iPCD Cohort was set up under the framework of the European Union (EU) funded 7th Framework Programme (FP7) project Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia (BESTCILIA). The iPCD Cohort is hosted at the Institute of Social and Preventive Medicine at the University of Bern, Switzerland. Research is performed in close collaboration with all data contributors. Aims: This combined international dataset allows investigation of PCD epidemiology in a large international study population in order to: 1) describe the spectrum of clinical phenotypes and disease severity in PCD patients by age, sex and time period of diagnosis; 2) describe short-term and long-term prognosis of PCD, looking at important outcomes such as growth, lung function and respiratory failure, bacterial colonisation, hearing loss, fertility, and mortality; and 3) identify predictors of long-term outcomes such as age at diagnosis, clinical phenotype, ultrastructural defects, genotype and clinical care. Study design: The iPCD Cohort is an international cohort, combining available data on PCD from national or local registries and clinical or diagnostic databases. All participating centres delivered retrospectively collected data; new centres joining the iPCD Cohort in the future can also participate with retrospectively and prospectively collected data. What information is collected: The iPCD Cohort includes retrospectively collected patient data on the following 11 thematic categories: 1) general information, 2) results of diagnostic tests, 3) baseline characteristics, 4) growth and lung function, 5) clinical manifestations, 6) therapy, 7) microbiology, 8) imaging, 9) surgical interventions, 10) neonatal period, and 11) family history. Study database: The iPCD Cohort database is web-based, using the Research Electronic Data Capture (REDCap) platform developed at Vanderbilt University. REDCap is widely used in academic research and allows data entry and extraction in various formats. How to participate: Centres that wish to participate to the project and contribute data can contact the iPCD Cohort to sign a data delivery agreement. They then will receive a password to access the online software REDCap and they will be able to enter their data directly. They can also upload follow-up data or add additional patients at a later time point. For further details, contact: pcd@ispm.unibe.ch Funding: The setting up of the iPCD Cohort (salaries, consumables and equipment) was funded by the EU FP7 project BESTCILIA (http://bestcilia.eu) and several Swiss funding bodies, including the Lung Leagues of Bern, St Gallen, Vaud, Ticino and Valais and the Milena Carvajal Pro-Kartagener Foundation. Data collection and management at each site was funded according to local arrangements. Most participating researchers and data contributors participate in the European Cooperation in Science and Technology (COST) Action "Better Evidence to Advance Therapeutic options for PCD" (BEAT-PCD) (BM 1407; www.beatpcd.org). Infrastructure is provided for free by the University of Bern, where the data are pooled and stored. The study is currently funded by the Swiss National Science Foundation (320030_173044 and 320030B_192804).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: December 2030
• Est. primary completion date: December 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Patients diagnosed with primary ciliary dyskinesia Exclusion Criteria: -

Related Conditions & MeSH terms

• Ciliary Motility Disorders
• Dyskinesias
• Kartagener Syndrome
• Primary Ciliary Dyskinesia

Locations

Country	Name	City	State
Switzerland	University of Bern	Bern

Sponsors (27)

Lead Sponsor

Collaborator

University of Bern

Amsterdam UMC, location VUmc, Attikon Hospital, Bar-Ilan University, Israel, Clinica de neumologia pediatrica Compensar, Copenhagen University Hospital, Denmark, European Commission, Genetic Disorders of Mucociliary Clearance Consortium, Hacettepe University, Hannover Medical School, Hospital de Niños R. Gutierrez de Buenos Aires, Institute of Tuberculosis and Lung Disorders, Rabka Poland, Marmara University, Medical Centre Dr Dragisa Misovic, Oslo University Hospital, Pierre and Marie Curie University, Royal Brompton & Harefield NHS Foundation Trust, Ruhr University of Bochum, Swiss National Science Foundation, University Hospital Muenster, University Hospital, Gasthuisberg, University Hospital, Motol, University of Cyprus, University of Leicester, University of Padova, University of Southampton, University of Sydney

Country where clinical trial is conducted

Switzerland, 

References & Publications (7)

Goutaki M, Halbeisen FS, Barbato A, Crowley S, Harris A, Hirst RA, Karadag B, Martinu V, Morgan L, O'Callaghan C, Ozcelik U, Scigliano S, Ucros S, Yiallouros P, Schulzke SM, Kuehni CE. Late Diagnosis of Infants with PCD and Neonatal Respiratory Distress. — View Citation

Goutaki M, Halbeisen FS, Spycher BD, Maurer E, Belle F, Amirav I, Behan L, Boon M, Carr S, Casaulta C, Clement A, Crowley S, Dell S, Ferkol T, Haarman EG, Karadag B, Knowles M, Koerner-Rettberg C, Leigh MW, Loebinger MR, Mazurek H, Morgan L, Nielsen KG, P — View Citation

Goutaki M, Maurer E, Halbeisen FS, Amirav I, Barbato A, Behan L, Boon M, Casaulta C, Clement A, Crowley S, Haarman E, Hogg C, Karadag B, Koerner-Rettberg C, Leigh MW, Loebinger MR, Mazurek H, Morgan L, Nielsen KG, Omran H, Schwerk N, Scigliano S, Werner C — View Citation

Halbeisen FS, Goutaki M, Spycher BD, Amirav I, Behan L, Boon M, Hogg C, Casaulta C, Crowley S, Haarman EG, Karadag B, Koerner-Rettberg C, Loebinger MR, Mazurek H, Morgan L, Nielsen KG, Omran H, Santamaria F, Schwerk N, Thouvenin G, Yiallouros P, Lucas JS, — View Citation

Halbeisen FS, Pedersen ESL, Goutaki M, Spycher BD, Amirav I, Boon M, Cohen-Cymberknoh M, Crowley S, Emiralioglu N, Haarman EG, Karadag B, Koerner-Rettberg C, Latzin P, Loebinger MR, Lucas JS, Mazurek H, Morgan L, Marthin J, Pohunek P, Santamaria F, Schwer — View Citation

Halbeisen FS, Shoemark A, Barbato A, Boon M, Carr S, Crowley S, Hirst R, Karadag B, Koerner-Rettberg C, Loebinger MR, Lucas JS, Maitre B, Mazurek H, Ozcelik U, Martinu V, Schwerk N, Thouvenin G, Tschanz SA, Yiallouros P, Goutaki M, Kuehni CE. Time trends — View Citation

Kouis P, Goutaki M, Halbeisen FS, Gioti I, Middleton N, Amirav I; Israeli PCD Consortium; Barbato A; Italian PCD Consortium; Behan L, Boon M, Emiralioglu N, Haarman EG, Karadag B, Koerner-Rettberg C, Lazor R; Swiss PCD Group; Loebinger MR, Maitre B; Frenc — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Height	Height z-scores calculated based on available national and international references	every 3 months up to 10 years
Primary	BMI	Body Mass Index (BMI) z-scores calculated based on available national and international references	every 3 months up to 10 years
Primary	Lung function measurements	Spirometric indices, particularly Forced expiratory volume in 1 sec (FEV1) and Forced vital capacity (FVC) z-scores calculated based on Global Lung Function Initiative (GLI) reference values	every 3 months up to 10 years
Primary	Diagnostic test results	Results of performed PCD diagnostic tests including measurement of nasal nitric oxide, electron microscopy findings, beat frequency and pattern.	at diagnosis/ study entry
Primary	Clinical symptoms and signs	Prevalence of reported clinical symptoms at different age groups, including rhinitis, cough, otitis, sinusitis, pneumonia, laterality defects, congenital heart disease and fertility problems.	every 3 months up to 10 years
Primary	Microbiology results	Results of microbiology cultures of respiratory samples (sputum, cough swabs, throat swabs, ear swabs, bronchoalveolar lavage) and information on antibiotic resistance (in positive cultures)	every 3 months up to 10 years
Primary	Imaging results	Radiological findings from sinus and lung imaging tests including x-rays, computed tomography and magnetic resonance imaging	every 3 months up to 10 years